Risk for active tuberculosis in inflammatory bowel disease patients

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 9, 2007, Pages 1070-1075.e1

  Aberra, Faten N ^a   Stettler, Nicolas ^a   Brensinger, Colleen ^a   Lichtenstein, Gary R ^a   Lewis, James D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CONFIDENCE INTERVAL; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFANT; MALE; MIDDLE AGED; PRESCHOOL CHILD; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDY; RISK; RISK FACTOR; SEX RATIO; TIME; TUBERCULOSIS; UNITED KINGDOM;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; INCIDENCE; INFANT; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; TIME FACTORS; TUBERCULOSIS;

EID: 35748974214     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.04.007     Document Type: Article

References (27)

1. Keane J, Gershon S, Wise R, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J Med 2001;345:1098-1104.
2. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368.
3. Anonymous. The General Practice Research Database: a guide for researchers. London: EPIC, Regeneration House, 2001.
4. Lis Y, Mann RD. The VAMP Research multi-purpose database in the U.K. J Clin Epidemiol 1995;48:431-443.
5. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-425.
6. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-768.
7. Lewis J, Brensinger C, Bilker W, et al. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2002;11: 211-218.
8. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005;129:819-826.
9. Lewis J, Bilker W, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080-1087.
10. Van Staa T-P, Cooper C, Brusse LS, et al. Inflammatory bowel disease and the risk for fracture. Gastroenterology 2003;125: 1591-1597.
11. Lewis JD, Bilker WB, Weinstein RB, et al. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005;14:443-451.
12. Lewis J, Brensinger C. Agreement between GPRD smoking data: a survey of general practitioners and a population-based survey. Pharmacoepidemiol Drug Saf 2004;epub Nov 26 2003.
13. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: WHO Technical Report Series, 2000.
14. Rose A, Watson J, Graham C. Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax 2002;56:173-179.
15. Duffield JS, Adams WH, Anderson M, et al. Increasing incidence of tuberculosis in the young and the elderly in Scotland. Thorax 1996;51:140-142.
16. Health Protection Agency, United Kingdom. Annual report on tuberculosis cases. Tuberculosis Section Health Protection Agency Centre for Infections. 2006.
17. Faubion WAJ, Loftus EVJ, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121: 255-260.
18. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-362.
19. Silverstein M, Loftus E, Sanborn W, et al. Clinical course and costs of care for Crohn's disease: Markow model analysis of a population-based cohort. Gastroenterology 1999;117:49-57.
20. Munkholm PLE, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
21. Lewis JLG, Brensinger C, Bilker W, et al. Characteristics of prior steroid use predicts duration of steroid therapy in inflammatory bowel disease (IBD). Gastroenterology 2001;120:A-269.
22. Faubion W, Loftus E, Harmsen W, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-260.
23. Bahr GM, Rook GA, Shahin A, et al. HLA-DR-associated isotypespecific regulation of antibody levels to mycobacteria in rheumatoid arthritis. Clin Exp Immunol 1988;72:26-31.
24. Mandell GL, Bennett JE, Dolin R, et al. Principles and practice of infectious diseases. New York: Churchill Livingstone, Inc, 2000.
25. Cline J, Davis S. Risks of infection or reactivation of tuberculosis associated with chronic corticosteroid therapy. Ann Pharmacol 1997;31:775-776.
26. Bateman E, Wolmarans K, White N, et al. Corticosteroids treatment and the risk of active tuberculosis in patients with chronic intestinal lung disease (abstract). Am Rev Respir Dis 1991;143: A54.
27. Sahn S, Lakshminarayan S. Tuberculosis after corticosteroid therapy. Br J Dis Chest 1976;70:195-205.